1: Mein S, Kopp B, Vela A, Dutheil P, Lesueur P, Stefan D, Debus J, Haberer T, Abdollahi A, Mairani A, Tessonnier T. How can we consider variable RBE and LETd prediction during clinical practice? A pediatric case report at the Normandy Proton Therapy Centre using an independent dose engine. Radiat Oncol. 2022 Feb 4;17(1):23. doi: 10.1186/s13014-021-01960-w. PMID: 35120547; PMCID: PMC8815260.

2: Doyen J, Aloi D, Groulier A, Vidal M, Lesueur P, Calugaru V, Bondiau PY. Role of proton therapy in reirradiation and in the treatment of sarcomas. Cancer Radiother. 2021 Oct;25(6-7):550-553. doi: 10.1016/j.canrad.2021.06.024. Epub 2021 Jul 17. PMID: 34284969.

3: Lesueur P, Doyen J, Lecornu M, Calugaru V, Florescu C, Missohou F, Geffrelot J, Mammar H, Stefan D, Feuvret L, Balosso J. Nouvelles indications de protonthérapie et essais cliniques en cours : tumeurs intracrâniennes [New indications of protontherapy for adults intracranial tumours]. Cancer Radiother. 2021 Oct;25(6-7):545-549. French. doi: 10.1016/j.canrad.2021.06.009. Epub 2021 Jun 24. PMID: 34175224.

4: Lecornu M, Lesueur P, Salleron J, Balosso J, Stefan D, Kao W, Plouhinec T, Vela A, Dutheil P, Bouter J, Marty PA, Thariat J, Quintyn JC. Prospective Assessment of Early Proton Therapy-Induced Optic Neuropathy in Patients With Intracranial, Orbital or Sinonasal Tumors: Impact of A Standardized Ophthalmological Follow Up. Front Oncol. 2021 Jun 15;11:673886. doi: 10.3389/fonc.2021.673886. PMID: 34211847; PMCID: PMC8239302.

5: Guigay J, Aupérin A, Fayette J, Saada-Bouzid E, Lafond C, Taberna M, Geoffrois L, Martin L, Capitain O, Cupissol D, Castanie H, Vansteene D, Schafhausen P, Johnson A, Even C, Sire C, Duplomb S, Evrard C, Delord JP, Laguerre B, Zanetta S, Chevassus-Clément C, Fraslin A, Louat F, Sinigaglia L, Keilholz U, Bourhis J, Mesia R; GORTEC; AIO; TTCC, and UniCancer Head and Neck groups. Cetuximab, docetaxel, and cisplatin versus platinum, luorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol. 2021 Apr;22(4):463-475. doi: 10.1016/S1470-2045(20)30755-5. Epub 2021 Mar 5. PMID: 33684370.

6: Tao Y, Aupérin A, Sun X, Sire C, Martin L, Coutte A, Lafond C, Miroir J, Liem X, Rolland F, Even C, Nguyen F, Saada E, Maillard A, Colin-Batailhou N, Thariat J, Guigay J, Bourhis J. Avelumab-cetuximab-radiotherapy versus standards of care in locally advanced squamous-cell carcinoma of the head and neck: The safety phase of a randomised phase III trial GORTEC 2017-01 (REACH). Eur J Cancer. 2020 Dec;141:21-29. doi: 10.1016/j.ejca.2020.09.008. Epub 2020 Oct 24. PMID: 33125944.

7: Sun XS, Tao Y, Le Tourneau C, Pointreau Y, Sire C, Kaminsky MC, Coutte A, Alfonsi M, Boisselier P, Martin L, Miroir J, Ramee JF, Delord JP, Clatot F, Rolland F, Villa J, Magne N, Elicin O, Gherga E, Nguyen F, Lafond C, Bera G, Calugaru V, Geoffrois L, Chauffert B, Zubel A, Zanna C, Brienza S, Crompton P, Rouits E, Gollmer K, Szyldergemajn S, Bourhis J. Debio 1143 and high-dose cisplatin chemoradiotherapy in high-risk locoregionally advanced squamous cell carcinoma of the head and neck: a double-blind, multicentre, randomised, phase 2 study. Lancet Oncol. 2020 Sep;21(9):1173-1187. doi: 10.1016/S1470-2045(20)30327-2. Epub 2020 Aug 3. PMID: 32758455.

8: Ollivier L, Guilloit JM, Dos Santos M, Guillemette L, Florescu C, M'vondo CM, Meyer E, Galais MP, Corbinais S, Parzy A, Varatharajah S, Lesueur P. Implantation of tissue expander prior to irradiation in the era of intensity modulated radiotherapy: impact on the management of patients with pelvic digestive cancers. Int J Colorectal Dis. 2020 Mar;35(3):559-564. doi: 10.1007/s00384-019-03475-z. Epub 2019 Dec 18. PMID: 31853620.

9: Lesueur P, Kao W, Leconte A, Geffrelot J, Lequesne J, Lacroix J, Brachet PE, Hrab I, Royer P, Clarisse B, Stefan D. Stereotactic radiotherapy on brain metastases with recent hemorrhagic signal: STEREO-HBM, a two-step phase 2 trial.
BMC Cancer. 2020 Feb 22;20(1):147. doi: 10.1186/s12885-020-6569-1. PMID: 32087691; PMCID: PMC7036220.

10: Lesueur P, Rapeaud E, De Marzi L, Goudjil F, Levy C, Galatoire O, Jacomet PV, Dendale R, Calugaru V. Adenoid Cystic Carcinoma of the Lacrimal Gland: High Dose Adjuvant Proton Therapy to Improve Patients Outcomes. Front Oncol. 2020 Feb 18;10:135. doi: 10.3389/fonc.2020.00135. PMID: 32133287; PMCID: PMC7041626.

11: Thariat J, Valable S, Laurent C, Haghdoost S, Pérès EA, Bernaudin M, Sichel F, Lesueur P, Césaire M, Petit E, Ferré AE, Saintigny Y, Skog S, Tudor M, Gérard M, Thureau S, Habrand JL, Balosso J, Chevalier F. Hadrontherapy Interactions in
Molecular and Cellular Biology. Int J Mol Sci. 2019 Dec 24;21(1):133. doi: 10.3390/ijms21010133. PMID: 31878191; PMCID: PMC6981652.

12: Dumont Lecomte D, Lequesne J, Geffrelot J, Lesueur P, Barraux V, Loiseau C, Lacroix J, Leconte A, Émery É, Thariat J, Stefan D. Hypofractionated stereotactic radiotherapy for challenging brain metastases using 36 Gy in six fractions. Cancer Radiother. 2019 Dec;23(8):860-866. doi: 10.1016/j.canrad.2019.06.012. Epub 2019 Oct 31. PMID: 31677901.

13: Boustani J, Rivin Del Campo E, Blanc J, Peiffert D, Benezery K, Pereira R, Rio E, Le Prisé E, Créhange G, Huguet F. Quality Assurance of Dose-Escalated Radiation Therapy in a Randomized Trial for Locally Advanced Oesophageal cancer. Int J Radiat Oncol Biol Phys. 2019 Oct 1;105(2):329-337. doi: 10.1016/j.ijrobp.2019.06.2542. Epub 2019 Jul 9. PMID: 31299242.

14: Gérard M, Corroyer-Dulmont A, Lesueur P, Collet S, Chérel M, Bourgeois M, Stefan D, Limkin EJ, Perrio C, Guillamo JS, Dubray B, Bernaudin M, Thariat J, Valable S. Hypoxia Imaging and Adaptive Radiotherapy: A State-of-the-Art Approach in the Management of Glioma. Front Med (Lausanne). 2019 Jun 12;6:117. doi: 10.3389/fmed.2019.00117. PMID: 31249831; PMCID: PMC6582242.

15: Legouté F, Bensadoun RJ, Seegers V, Pointreau Y, Caron D, Lang P, Prévost A, Martin L, Schick U, Morvant B, Capitain O, Calais G, Jadaud E. Low-level laser therapy in treatment of chemoradiotherapy-induced mucositis in head and neck cancer: results of a randomised, triple blind, multicentre phase III trial. Radiat Oncol. 2019 May 22;14(1):83. doi: 10.1186/s13014-019-1292-2. PMID: 31118057; PMCID: PMC6530019.

16: Lesueur P, Lequesne J, Grellard JM, Dugué A, Coquan E, Brachet PE, Geffrelot J, Kao W, Emery E, Berro DH, Castera L, Goardon N, Lacroix J, Lange M, Capel A, Leconte A, Andre B, Léger A, Lelaidier A, Clarisse B, Stefan D. Phase I/IIa study of concomitant radiotherapy with olaparib and temozolomide in unresectable or partially resectable glioblastoma: OLA-TMZ-RTE-01 trial protocol. BMC Cancer. 2019 Mar 4;19(1):198. doi: 10.1186/s12885-019-5413-y. PMID: 30832617; PMCID: PMC6399862.

17: Chevalier F, Hamdi DH, Lepleux C, Temelie M, Nicol A, Austry JB, Lesueur P, Vares G, Savu D, Nakajima T, Saintigny Y. High LET Radiation Overcomes In Vitro Resistance to X-Rays of Chondrosarcoma Cell Lines. Technol Cancer Res Treat. 2019 Jan 1;18:1533033819871309. doi: 10.1177/1533033819871309. PMID: 31495269; PMCID: PMC6732854.

18: Lesueur P, Calugaru V, Nauraye C, Stefan D, Cao K, Emery E, Reznik Y, Habrand JL, Tessonnier T, Chaikh A, Balosso J, Thariat J. Proton therapy for treatment of intracranial benign tumors in adults: A systematic review. Cancer Treat Rev. 2019 Jan;72:56-64. doi: 10.1016/j.ctrv.2018.11.004. Epub 2018 Dec 1. PMID: 30530009.

19: Lesueur P, Escande A, Thariat J, Vauléon E, Monnet I, Cortot A, Lerouge D, Danhier S, Dô P, Dubos-Arvis C, Chouaïd C, Gervais R. Safety of combined PD-1 pathway inhibition and radiation therapy for non-small-cell lung cancer: A multicentric retrospective study from the GFPC. Cancer Med. 2018 Nov;7(11):5505-5513. doi: 10.1002/cam4.1825. Epub 2018 Oct 11. Erratum in: Cancer Med. 2019 Sep;8(12):5820. PMID: 30311424; PMCID: PMC6247050.

20: Lesueur P, Martel-Laffay I, Escande A, Kissel M, Locher C, Gervais R, Schott R, Vergnenegre A, Chouaid C. Oral vinorelbine-based concomitant chemoradiotherapy in unresectable stage III non-small cell lung cancer: a systematic review. Expert Rev Anticancer Ther. 2018 Nov;18(11):1159-1165. doi: 10.1080/14737140.2018.1518714. Epub 2018 Sep 17. PMID: 30173589.

21: Geoffrois L, Martin L, De Raucourt D, Sun XS, Tao Y, Maingon P, Buffet J, Pointreau Y, Sire C, Tuchais C, Babin E, Coutte A, Rolland F, Kaminsky MC, Alfonsi M, Lapeyre M, Saliou M, Lafond C, Jadaud E, Gery B, Zawadi A, Tourani JM, Khoury C, Henry AR, Hasbini A, Guichard F, Borel C, Meert N, Guillet P, Calais MH, Garaud P, Bourhis J. Induction Chemotherapy Followed by Cetuximab Radiotherapy Is Not Superior to Concurrent Chemoradiotherapy for Head and Neck Carcinomas: Results of the GORTEC 2007-02 Phase III Randomized Trial. J Clin Oncol. 2018 Nov 1;36(31):3077-3083. doi: 10.1200/JCO.2017.76.2591. Epub 2018 Jul 17. PMID: 30016178.

22: Charret J, Salleron J, Quivrin M, Mazoyer F, Lesueur P, Martin E, Peiffert D, Créhange G. Impact of rectal distension on prostate CBCT-based positioning assessed with 6 degrees-of-freedom couch. Pract Radiat Oncol. 2018 Sep-Oct;8(5):e322-e328. doi: 10.1016/j.prro.2018.03.001. Epub 2018 Mar 9. PMID: 29706305.

23: Lesueur P, Lequesne J, Barraux V, Kao W, Geffrelot J, Grellard JM, Habrand JL, Emery E, Marie B, Thariat J, Stefan D. Radiosurgery or hypofractionated stereotactic radiotherapy for brain metastases from radioresistant primaries (melanoma and renal cancer). Radiat Oncol. 2018 Jul 28;13(1):138. doi: 10.1186/s13014-018-1083-1. PMID: 30055640; PMCID: PMC6064124.

24: Tao Y, Auperin A, Sire C, Martin L, Khoury C, Maingon P, Bardet E, Kaminsky MC, Lapeyre M, Chatellier T, Alfonsi M, Pointreau Y, Jadaud E, Géry B, Zawadi A, Tourani JM, Laguerre B, Coutte A, Racadot S, Hasbini A, Malaurie E, Borel C, Meert N, Cornely A, Ollivier N, Casiraghi O, Sun XS, Bourhis J. Improved Outcome by Adding Concurrent Chemotherapy to Cetuximab and Radiotherapy for Locally Advanced Head and Neck Carcinomas: Results of the GORTEC 2007-01 Phase III Randomized Trial. J Clin Oncol. 2018 Jun 7:JCO2017762518. doi: 10.1200/JCO.2017.76.2518. Epub ahead of print. PMID: 29878867.

25: Thariat J, Habrand JL, Lesueur P, Chaikh A, Kammerer E, Lecomte D, Batalla A, Balosso J, Tessonnier T. Apports de la protonthérapie à la radiothérapie d’aujourd’hui, pourquoi, comment ? [Why proton therapy? And how?]. Bull Cancer. 2018 Mar;105(3):315-326. French. doi: 10.1016/j.bulcan.2017.12.004. PMID: 29422248.

26: Lesueur P, Chevalier F, El-Habr EA, Junier MP, Chneiweiss H, Castera L, Müller E, Stefan D, Saintigny Y. Radiosensitization Effect of Talazoparib, a Parp Inhibitor, on Glioblastoma Stem Cells Exposed to Low and High Linear Energy Transfer Radiation. Sci Rep. 2018 Feb 26;8(1):3664. doi: 10.1038/s41598-018-22022-4. PMID: 29483558; PMCID: PMC5826933.

27: Lesueur P, Chevalier F, Austry JB, Waissi W, Burckel H, Noël G, Habrand JL, Saintigny Y, Joly F. Poly-(ADP-ribose)-polymerase inhibitors as radiosensitizers: a systematic review of pre-clinical and clinical human studies. Oncotarget. 2017 Jul 7;8(40):69105-69124. doi: 10.18632/oncotarget.19079. PMID: 28978184; PMCID: PMC5620324.

28: Tao Y, Aupérin A, Graff P, Lapeyre M, Grégoire V, Maingon P, Geoffrois L, Verrelle P, Calais G, Gery B, Martin L, Alfonsi M, Deprez P, Bardet E, Pignon T, Rives M, Sire C, Bourhis J. Very accelerated radiotherapy or concurrent chemoradiotherapy for N3 head and neck squamous cell carcinoma: Pooled analysis of two GORTEC randomized trials. Oral Oncol. 2017 Aug;71:61-66. doi: 10.1016/j.oraloncology.2017.06.002. Epub 2017 Jun 9. PMID: 28688693.

29: Lesueur P, Chevalier F, Stefan D, Habrand JL, Lerouge D, Gervais R. Review of the mechanisms involved in the abscopal effect and future directions with a focus on thymic carcinoma. Tumori. 2017 May 12;103(3):217-222. doi: 10.5301/tj.5000616. Epub 2017 Mar 3. PMID: 28291902.

30: Lesueur P, Servagi-Vernat S. Détermination des marges du volume cible anatomoclinique au volume cible prévisionnel pour la radiothérapie conformationnelle des cancers de l'œsophage [Definition of accurate planning target volume margins for esophageal cancer radiotherapy]. Cancer Radiother. 2016 Oct;20(6-7):651-6. French. doi: 10.1016/j.canrad.2016.07.065. Epub 2016 Sep 3. PMID: 27599683.

31: Stefan D, Popotte H, Stefan AR, Tesniere A, Tomaszewski A, Lesueur P, Habrand JL, Verneuil L. Vemurafenib and concomitant stereotactic radiation for the treatment of melanoma with spinal metastases: A case report. Rep Pract Oncol Radiother. 2016 Jan-Feb;21(1):76-80. doi: 10.1016/j.rpor.2015.07.005. Epub 2015 Sep 29. PMID: 26900362; PMCID: PMC4716399.

32: Sassier M, Dugué AE, Clarisse B, Lesueur P, Avrillon V, Bizieux-Thaminy A, Auliac JB, Kaluzinski L, Tillon J, Robinet G, Le Caer H, Monnet I, Madroszyk A, Boza G, Falchero L, Fournel P, Egenod T, Toffart AC, Leiber N, Do P, Gervais R. Renal insufficiency is the leading cause of double maintenance (bevacizumab and pemetrexed) discontinuation for toxicity to advanced non-small cell lung cancer in real world setting. Lung Cancer. 2015 Aug;89(2):161-6. doi: 10.1016/ .lungcan.2015.05.005. Epub 2015 May 15. PMID: 26037036.

33: Martin L, Zoubir M, Le Tourneau C. Les récidives des tumeurs des voies aérodigestives supérieures [Recurrence of upper aerodigestive tract tumors]. Bull Cancer. 2014 May 1;101(5):511-20. French. doi: 10.1684/bdc.2014.1970. PMID:
24886903.

34: Bourhis J, Sire C, Graff P, Grégoire V, Maingon P, Calais G, Gery B, Martin L, Alfonsi M, Desprez P, Pignon T, Bardet E, Rives M, Geoffrois L, Daly-Schveitzer N, Sen S, Tuchais C, Dupuis O, Guerif S, Lapeyre M, Favrel V, Hamoir M, Lusinchi A, Temam S, Pinna A, Tao YG, Blanchard P, Aupérin A. Concomitant chemoradiotherapy versus acceleration of radiotherapy with or without concomitant chemotherapy in locally advanced head and neck carcinoma (GORTEC 99-02): an open-label phase 3 randomised trial. Lancet Oncol. 2012 Feb;13(2):145-53. doi: 10.1016/S1470-2045(11)70346-1. Epub 2012 Jan 18. PMID: 22261362.

35: Cellier P, Leduc B, Martin L, Vié B, Chevelle C, Vendrely V, Salemkour A, Carrie C, Calais G, Burtin P, Campion L, Boisdron-Celle M, Morel A, Berger V, Gamelin E. Phase II study of preoperative radiation plus concurrent daily tegafur-uracil (UFT) with leucovorin for locally advanced rectal cancer. BMC Cancer. 2011 Mar 16;11:98. doi: 10.1186/1471-2407-11-98. PMID: 21410976; PMCID: PMC3070684.

36: Bardet E, Martin L, Calais G, Alfonsi M, Feham NE, Tuchais C, Boisselier P, Dessard-Diana B, Seng SH, Garaud P, Aupérin A, Bourhis J. Subcutaneous compared with intravenous administration of amifostine in patients with head and neck
cancer receiving radiotherapy: final results of the GORTEC2000-02 phase III randomized trial. J Clin Oncol. 2011 Jan 10;29(2):127-33. doi: 10.1200/JCO.2009.25.5638. Epub 2010 Nov 29. PMID: 21115863.

37: Beauchesne P, Bernier V, Carnin C, Taillandier L, Djabri M, Martin L, Michel X, Maire JP, Khalil T, Kerr C, Gorlia T, Stupp R, Pedeux R. Prolonged survival for patients with newly diagnosed, inoperable glioblastoma with 3-times daily
ultrafractionated radiation therapy. Neuro Oncol. 2010 Jun;12(6):595-602. doi: 10.1093/neuonc/noq008. Epub 2010 Feb 11. PMID: 20511183; PMCID: PMC2940649.

38: Buiret G, Combe C, Favrel V, Pommier P, Martin L, Ecochard R, Fayette J, Tartas S, Ramade A, Céruse P. A retrospective, multicenter study of the tolerance of induction chemotherapy with docetaxel, Cisplatin, and 5-Fluorouracil followed by radiotherapy with concomitant cetuximab in 46 cases of squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys. 2010 Jun 1;77(2):430-7. doi: 10.1016/j.ijrobp.2009.04.066. Epub 2009 Sep 21. PMID: 19775831.

39: Fesneau M, Pointreau Y, Chapet S, Martin L, Pommier P, Alfonsi M, Laguerre B, Feham N, Berger C, Garaud P, Calais G. Concomitant chemoradiotherapy using carboplatin, tegafur-uracil and leucovorin for stage III and IV head-and-neck
cancer: results of GORTEC Phase II study. Int J Radiat Oncol Biol Phys. 2010 Jan 1;76(1):154-63. doi: 10.1016/j.ijrobp.2009.01.033. PMID: 19386430.

40: Hebbar M, Di Fioré F, Conroy T, Giraud C, Gasnault L, Fournier C, Péreira R, Bouché O, Fournier P, Deligny N, Joly JP, Maes P, Rad E, Michel P, Adenis A. Assessment of baseline clinical predictive factors of response to cetuximab-irinotecan in patients with irinotecan-refractory metastatic colorectal cancer. Oncology. 2007;73(3-4):185-91. doi: 10.1159/000127385. Epub 2008 Apr 16. PMID: 18418011.

41: Denis F, Garaud P, Bardet E, Alfonsi M, Sire C, Germain T, Bergerot P, Rhein B, Tortochaux J, Oudinot P, Calais G. Late toxicity results of the GORTEC 94-01 randomized trial comparing radiotherapy with concomitant radiochemotherapy for
advanced-stage oropharynx carcinoma: comparison of LENT/SOMA, RTOG/EORTC, and NCI-CTC scoring systems. Int J Radiat Oncol Biol Phys. 2003 Jan 1;55(1):93-8. doi: 10.1016/s0360-3016(02)03819-1. PMID: 12504040.

42: Calais G, Alfonsi M, Bardet E, Sire C, Germain T, Bergerot P, Rhein B, Tortochaux J, Oudinot P, Bertrand P. Cancers de l'oropharynx de stades III et IV: résultats d'une étude randomisée du Gortec comparant radiothérapie exclusive et radiothérapie avec chimiothérapie concomitante [Stage III and IV cancers of the oropharynx: results of a randomized study of Gortec comparing radiotherapy alone with concomitant chemotherapy]. Bull Cancer. 2000 Aug;87 Spec No:48-53. French. PMID: 11082723.

43: Calais G, Alfonsi M, Bardet E, Sire C, Germain T, Bergerot P, Rhein B, Tortochaux J, Oudinot P, Bertrand P. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst. 1999 Dec 15;91(24):2081-6. doi: 10.1093/jnci/91.24.2081. PMID: 10601378.

44: Arriagada R, Mouriesse H, Spielmann M, Mezlini A, Oudinot P, le Chevalier T, Cuvier C, Fontaine F, Travagli JP, May-Levin F, et al. Alternating radiotherapy and chemotherapy in non-metastatic inflammatory breast cancer. Int J Radiat Oncol Biol Phys. 1990 Nov;19(5):1207-10. doi: 10.1016/0360-3016(90)90230-h. PMID: 2254114.

45: Rouëssé J, Sarrazin D, Spielmann M, Le Chevalier T, Oudinot P, Guasch Jordan I, Mouriesse H, Levin FM. Le traitement du cancer du sein inflammatoire. Associations chimiothérapie-radiothérapie. A propos de 270 femmes traitées à l'Institut Gustave-Roussy [Treatment of inflammatory cancer of the breast. Combined chemotherapy and radiotherapy. Apropos of 270 women treated at the Institut Gustave-Roussy]. Bull Cancer. 1989;76(1):87-92. French. PMID: 2713518.

46: Martin ED, Bedossa P, Oudinot P. Les lésions de la région oddienne: fréquence et association à des lésions biliares et pancréatiques dans une série de 109 autopsies [Lesions of the area of Oddi's sphincter: incidence and association with biliary and pancreatic lesions in a series of 109 autopsies]. Gastroenterol Clin Biol. 1987 Aug-Sep;11(8-9):574-80. French. PMID: 3653618.

47: Lesueur P, Damaj G, Hoang-Xuan K, Roland V, Schmitt A, Chinot O, et al. Reduced-dose WBRT as consolidation treatment for patients with primary CNS lymphoma: a LOC-network study. Blood Adv 2022:bloodadvances.2022007011. https://doi.org/10.1182/bloodadvances.2022007011.

48: Chevalier F, Lesueur P, Gaubert G. CYCLHAD: A French Facility Dedicated for Research and Treatment in Hadrontherapy. Nucl Phys News 2022;32:27–31)